3R Pharma is developing high-end and complex cannabinoid-based pharmaceutical products to address chronic ocular diseases for patients around the world. These patent-pending cannabinoid-based medicines provide a novel treatment option for various conditions that are currently insufficiently addressed. The company's R&D unit, based in Israel, is licensed to conduct scientific and clinical research on cannabinoid formulations by the Ministry of Health IMC.